# Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

> **NCT01492686** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 137 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** MCI-186
- **DRUG:** Placebo
- **DRUG:** MCI-186 in open label phase

## Key facts

- **NCT ID:** NCT01492686
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-09
- **Final completion:** 2014-10
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01492686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01492686, "Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01492686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*